Tarsus Pharmaceuticals Inc (NAS:TARS)

$ 28.93 1.38 (5.01%) Market Cap: 1.09 Bil Enterprise Value: 825.02 Mil PE Ratio: 0 PB Ratio: 3.97 GF Score: 60/100

Q1 2024 Tarsus Pharmaceuticals Inc Earnings Call Transcript
May 08, 2024

$37.35 (-1.79%)

Earnings
Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call Transcript
Feb 27, 2024

$39.22 (+18.28%)

Earnings
Q3 2023 Tarsus Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2023

$15.57 (-5.86%)

Earnings
Tarsus Pharmaceuticals Inc To Discuss XDEMVY Approved For The Treatment Of Demodex Blepharitis Call Transcript
Jul 25, 2023
Tarsus Pharmaceuticals Inc To Discuss Creating the Next Blockbuster Category in Eye Care Call Transcript
Jun 15, 2023
Tarsus Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Tarsus Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2023
Tarsus Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Tarsus Pharmaceuticals Inc To Discuss Revolutionizing Treatment For Demodex Blepharitis Patients Call Transcript
Feb 08, 2022
Tarsus Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 08, 2021
Tarsus Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Tarsus Pharmaceuticals Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 22, 2021
Tarsus Pharmaceuticals Inc Saturn-1 Pivotal Trial Topline Results Call Transcript
Jun 21, 2021

Tarsus Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 08, 2021 / 07:40PM GMT

Release Date Price: $28 (+0.47%)

Transcript 10-Q8-K

Liav Abraham

Credit Suisse - Analyst

I'm very pleased to have with me this afternoon, Bobby Azamian, who is the CEO of Tarsus Pharmaceuticals, an exciting development stage company in the ophthalmology space. The way we're going to structure this is, Bobby is going to present the company for a few minutes and thereafter, we'll engage in some back-and-forth Q&A. If anyone has a question that they'd like to ask, I'm more than happy to do so on your behalf. Feel free to e-mail me at [email protected].

So with the formalities out of the way, Bobby, over to you. Thanks very much for being with us and looking forward to hearing what you have to say.

Bobby Azamian

Tarsus Pharmaceuticals, Inc. - CEO & Chairman

Thank you, Liav, thanks for the opportunity. So thanks for the opportunity to present today at the Credit Suisse conference. I have a short slide deck here to introduce Tarsus and look forward to the Q&A afterwards. A short disclaimer, I will be making forward-looking statements in this presentation.

And to introduce

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.